Westfuller Advisors LLC Buys 3,860 Shares of Johnson & Johnson $JNJ

Westfuller Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 107.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,440 shares of the company’s stock after purchasing an additional 3,860 shares during the quarter. Westfuller Advisors LLC’s holdings in Johnson & Johnson were worth $1,379,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in JNJ. Evolution Wealth Management Inc. purchased a new position in shares of Johnson & Johnson in the second quarter valued at $27,000. Clayton Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $28,000. Semmax Financial Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at approximately $35,000. Finally, Signature Resources Capital Management LLC lifted its position in Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after buying an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JNJ. Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. The Goldman Sachs Group reissued a “buy” rating and issued a $250.00 price objective on shares of Johnson & Johnson in a research report on Thursday. Morgan Stanley boosted their target price on Johnson & Johnson from $197.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday. Raymond James Financial increased their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Finally, Barclays raised their price target on Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $226.18.

Johnson & Johnson Price Performance

Shares of JNJ opened at $220.29 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a 50 day moving average price of $208.35 and a 200-day moving average price of $189.39. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $222.17. The stock has a market capitalization of $530.74 billion, a PE ratio of 19.94, a PEG ratio of 2.14 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting analysts’ consensus estimates of $2.46. The company had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. Johnson & Johnson’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.